Bosentan
![TRACLEER® [Bosentan] 62.5 Mg and 125 Mg Film-Coated Tablets](http://data.docslib.org/img/264x/16b3842edfed0c7e0234834252a66a72.webp)
Top View
- PDL)/Non-Preferred Drug List (NPDL
- Endothelin ETA Receptor Blockade, by Activating ETB Receptors, Increases Vascular Permeability and Induces Exaggerated Fluid Retention S
- Advanced Control Specialty Formulary® Is a Guide Within Select Therapeutic Categories for Clients, Plan Members and Health Care Providers
- E-Binder March 2021
- Distinct ETA Receptor Binding Mode of Macitentan As Determined by Site Directed Mutagenesis
- NEW--Npf-MASTER LIST.Xlsx
- Lemborexant (Dayvigo™) New Drug Update
- (12) United States Patent (10) Patent No.: US 8,664,390 B2 Gaitonde Et Al
- Sitaxsentan Proves Effective in Pulmonary Arterial Hypertension
- Blue Cross and Blue Shield October 2019 Multi-Tier Basic Drug List I How to Use This List Generic Drugs Are Shown in Lower-Case Boldface Type
- Lemborexant (Dayvigo®) FDA Approved December 2019 (Eisai Inc); Schedule IV Controlled Substance
- Medicaid Health Plan Common Formulary
- Final Decisions and Reasons for Decisions by Delegates of the Secretary to the Department of Health
- FEP 5 Tier Rx Drug Formulary (607) Standard Option
- Provider Memorandum Dated August 26, 2020
- TRACLEER (Bosentan)
- Endothelin Receptor Antagonists (Eras) Annual Review Date: Tracleer (Bosentan) 1/21/2021 Letairis (Ambrisentan) Opsumit (Macitentan) Last Revised Date: 2/18/2021
- Sitaxentan-Related Acute Liver Failure in a Patient with Pulmonary Arterial Hypertension